An Observational Study to Evaluate the Effectiveness of Mircera Treatment for Renal Anemia in Pre-dialysis Participants With Chronic Kideny Disease (CKD)

• Status: Completed
• Trial end date: 2014-11-30
• Target enrollment: 0
• Participant gender: All

Summary

This observational trial will examine the efficacy and safety of Mircera for renal anemia in participants with stage III-IV CKD in daily clinical practice. Mircera will be prescribed by treating physician and followed for approximately 36 months.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hoffmann-La Roche
• Treatments: Epoetin Alfa

Criteria

Inclusion Criteria:

• Participants aged > 18 years with CKD

• Participants who are eligible for Mircera treatment according to current guidelines and summary of product characteristics (SmPC)

Exclusion Criteria:

• Non-renal anemia

• Pregnancy and breast-feeding

• Uncontrolled hypertension

• Known hypersensitivity to methoxy polyethylene glycol-epoetin beta

• Administration of any other study drug within 30 days prior to study enrollment